HRP20010194B1 - Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments - Google Patents

Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments

Info

Publication number
HRP20010194B1
HRP20010194B1 HR20010194A HRP20010194A HRP20010194B1 HR P20010194 B1 HRP20010194 B1 HR P20010194B1 HR 20010194 A HR20010194 A HR 20010194A HR P20010194 A HRP20010194 A HR P20010194A HR P20010194 B1 HRP20010194 B1 HR P20010194B1
Authority
HR
Croatia
Prior art keywords
group
unbranched
branched
alkyl
polysubstituted
Prior art date
Application number
HR20010194A
Other languages
English (en)
Croatian (hr)
Inventor
Eickmeier Christian
Buerger Erich
Matthias Blech Stefan
Roos Otto
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg.
Publication of HRP20010194A2 publication Critical patent/HRP20010194A2/hr
Publication of HRP20010194B1 publication Critical patent/HRP20010194B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
HR20010194A 1998-09-22 2001-03-15 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments HRP20010194B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19843489A DE19843489B4 (de) 1998-09-22 1998-09-22 Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung
PCT/EP1999/006857 WO2000017176A2 (de) 1998-09-22 1999-09-16 Benzolylguanidin-abkömmlinge mit vorteilhaften eigenschaften, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von arzneimiteln

Publications (2)

Publication Number Publication Date
HRP20010194A2 HRP20010194A2 (en) 2002-04-30
HRP20010194B1 true HRP20010194B1 (en) 2009-05-31

Family

ID=7881872

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010194A HRP20010194B1 (en) 1998-09-22 2001-03-15 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments

Country Status (35)

Country Link
EP (1) EP1165534B1 (es)
JP (1) JP3817425B2 (es)
KR (1) KR100621821B1 (es)
CN (1) CN1166654C (es)
AR (1) AR023668A1 (es)
AT (1) ATE288425T1 (es)
AU (1) AU764819C (es)
BG (1) BG64985B1 (es)
BR (1) BR9913107A (es)
CA (1) CA2345006C (es)
CO (1) CO5150207A1 (es)
CZ (1) CZ300158B6 (es)
DE (2) DE19843489B4 (es)
EA (1) EA004687B1 (es)
EE (1) EE04749B1 (es)
EG (1) EG23757A (es)
ES (1) ES2237951T3 (es)
HK (1) HK1043367B (es)
HR (1) HRP20010194B1 (es)
HU (1) HU228955B1 (es)
ID (1) ID27759A (es)
IL (1) IL141805A (es)
MY (1) MY121362A (es)
NO (1) NO317993B1 (es)
NZ (1) NZ511167A (es)
PE (1) PE20001085A1 (es)
PL (1) PL195291B1 (es)
PT (1) PT1165534E (es)
RS (1) RS49971B (es)
SA (1) SA99200474B1 (es)
SK (1) SK285578B6 (es)
TR (1) TR200100801T2 (es)
TW (1) TWI221841B (es)
WO (1) WO2000017176A2 (es)
ZA (1) ZA200101212B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
FR2871157A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Produits biaryl aromatiques, compositions les contenant et utilisation
WO2010005783A1 (en) * 2008-07-08 2010-01-14 Boehringer Ingelheim International Gmbh Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
ZA200101212B (en) 2002-10-04
ES2237951T3 (es) 2005-08-01
KR20010079884A (ko) 2001-08-22
EE200100178A (et) 2002-10-15
PL195291B1 (pl) 2007-08-31
HK1043367B (zh) 2005-02-25
HUP0200225A2 (en) 2002-06-29
BR9913107A (pt) 2002-06-11
PL347234A1 (en) 2002-03-25
CA2345006C (en) 2007-11-13
AU764819B2 (en) 2003-08-28
YU21501A (sh) 2004-03-12
PE20001085A1 (es) 2000-10-25
TWI221841B (en) 2004-10-11
CZ20011047A3 (cs) 2001-08-15
IL141805A (en) 2005-12-18
MY121362A (en) 2006-01-28
DE19843489B4 (de) 2006-12-21
EG23757A (en) 2007-08-08
SK285578B6 (sk) 2007-04-05
EP1165534B1 (de) 2005-02-02
AU6465999A (en) 2000-04-10
EE04749B1 (et) 2006-12-15
CN1342153A (zh) 2002-03-27
JP2002538077A (ja) 2002-11-12
NO20011428L (no) 2001-03-21
SA99200474B1 (ar) 2006-06-10
CO5150207A1 (es) 2002-04-29
EA200100317A1 (ru) 2001-10-22
RS49971B (sr) 2008-09-29
HRP20010194A2 (en) 2002-04-30
DE59911568D1 (de) 2005-03-10
PT1165534E (pt) 2005-04-29
HK1043367A1 (en) 2002-09-13
CA2345006A1 (en) 2000-03-30
NZ511167A (en) 2003-12-19
BG64985B1 (bg) 2006-11-30
WO2000017176A3 (de) 2001-10-11
CZ300158B6 (cs) 2009-02-25
DE19843489A1 (de) 2000-03-23
WO2000017176A2 (de) 2000-03-30
ATE288425T1 (de) 2005-02-15
SK3962001A3 (en) 2001-10-08
ID27759A (id) 2001-04-26
EA004687B1 (ru) 2004-06-24
KR100621821B1 (ko) 2006-09-13
BG105326A (en) 2001-11-30
NO317993B1 (no) 2005-01-17
TR200100801T2 (tr) 2002-04-22
NO20011428D0 (no) 2001-03-21
CN1166654C (zh) 2004-09-15
JP3817425B2 (ja) 2006-09-06
AU764819C (en) 2004-12-16
IL141805A0 (en) 2002-03-10
HU228955B1 (en) 2013-07-29
EP1165534A2 (de) 2002-01-02
AR023668A1 (es) 2002-09-04
HUP0200225A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
IS4588A (is) Bensimídazól efnasambönd, lyfjablöndur sem innihalda efnasamböndin og notkun þeirra
BRPI0312811A8 (pt) monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica
HUP0402026A2 (hu) 5,6-Diaril-pirazin-2-amid-származékok mint CB1 antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO980313D0 (no) N-(Aroyl)glysin-hydroksamsyre-derivater og beslektete forbindelser
RS52326B (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
EP1344525A4 (en) ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM
MEP52408A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
RS51155B (sr) DERIVATI α -(N-SULFONAMIDO)ACETAMIDA KAO INHIBITORI β -AMILOIDA
NO20051051L (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler
CO5601029A2 (es) Inhibidores no nucleosidos de transcriptasa inversa i para el tratamiento de enfermedades mediadas por vih
BR0009411A (pt) Composto de anilina substituìda, e, processo para a preparação e uso de compostos
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
NO974843D0 (no) Benzimidazolforbindelser, farmasöytiske sammensetninger som inneholder forbindelsene og deres anvendelser
RS51681B (sr) Piperazinil i diazapanil benzamidi i benztioamidi
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
FI962418A (fi) Syklisiä amidijohdannaisia neurokiniini A antagonisteina
EA200500690A1 (ru) Новые соединения пиридопиримидинона, способ их получения и фармацевтические композиции, которые их содержат
HRP20010194B1 (en) Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments
ATE111098T1 (de) Substituierte n-(3-hydroxy-4- piperidinyl)benzamide.
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
EA199901096A1 (ru) Цианогуанидины в качестве ингибиторов пролиферации клеток
NO20002124L (no) Nye karboksylsyrederivater med amid-sidekjeder, deres fremstilling og anvendelse som endothelin-reseptorantagonister
ATE246177T1 (de) Katecholhydrazon-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG., DE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150824

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20160916